EP1009433A4 - Therapeutische zusammensetzung und verfahren zur behandlung - Google Patents

Therapeutische zusammensetzung und verfahren zur behandlung

Info

Publication number
EP1009433A4
EP1009433A4 EP98931277A EP98931277A EP1009433A4 EP 1009433 A4 EP1009433 A4 EP 1009433A4 EP 98931277 A EP98931277 A EP 98931277A EP 98931277 A EP98931277 A EP 98931277A EP 1009433 A4 EP1009433 A4 EP 1009433A4
Authority
EP
European Patent Office
Prior art keywords
treatment
therapeutic composition
therapeutic
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98931277A
Other languages
English (en)
French (fr)
Other versions
EP1009433A1 (de
Inventor
Thomas R Sykes
Ragupathy Madiyalakan
Richard P Baum
Antoine A Noujaim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altarex Medical Corp
Original Assignee
Altarex Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/877,511 external-priority patent/US6086873A/en
Application filed by Altarex Medical Corp filed Critical Altarex Medical Corp
Publication of EP1009433A1 publication Critical patent/EP1009433A1/de
Publication of EP1009433A4 publication Critical patent/EP1009433A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP98931277A 1997-06-17 1998-06-16 Therapeutische zusammensetzung und verfahren zur behandlung Withdrawn EP1009433A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/877,511 US6086873A (en) 1996-05-15 1997-06-17 Therapeutic composition and method of treatment
US877511 1997-06-17
PCT/US1998/012401 WO1998057661A1 (en) 1997-06-17 1998-06-16 Therapeutic composition and method of treatment

Publications (2)

Publication Number Publication Date
EP1009433A1 EP1009433A1 (de) 2000-06-21
EP1009433A4 true EP1009433A4 (de) 2005-03-16

Family

ID=25370129

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98931277A Withdrawn EP1009433A4 (de) 1997-06-17 1998-06-16 Therapeutische zusammensetzung und verfahren zur behandlung

Country Status (5)

Country Link
EP (1) EP1009433A4 (de)
JP (1) JP2002504154A (de)
AU (1) AU732505B2 (de)
CA (1) CA2292912A1 (de)
WO (1) WO1998057661A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361346B1 (en) 1996-05-15 2008-04-22 Altarex Corp. Therapeutic compositions that produce an immune response
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
US7318921B2 (en) 1996-05-15 2008-01-15 Altarex Medical Corp. Therapeutic compositions that alter the immune response
CA2333221A1 (en) * 1998-06-15 1999-12-23 Altarex Corp. Therapeutic compositions that produce an immune response by altering the antigen
CA2481796A1 (en) * 2002-04-11 2003-10-23 Altarex Medical Corporation Binding agents and their use in targeting tumor cells
US7605143B2 (en) 2004-08-02 2009-10-20 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018792A1 (en) * 1992-03-18 1993-09-30 Biomira Inc. Selective alteration of antibody immunogenicity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018792A1 (en) * 1992-03-18 1993-09-30 Biomira Inc. Selective alteration of antibody immunogenicity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; February 1996 (1996-02-01), STALTERI M A ET AL: "Technetium-99m labelling of the anti-tumour antibody PR1A3 by photoactivation.", XP002313121, Database accession no. NLM8925853 *
See also references of WO9857661A1 *
STALTERI M A ET AL: "Technetium-99m labelling of the anti-tumour antibody PR1A3 by photoactivation.", February 1996, EUROPEAN JOURNAL OF NUCLEAR MEDICINE. FEB 1996, VOL. 23, NR. 2, PAGE(S) 178 - 187, ISSN: 0340-6997 *

Also Published As

Publication number Publication date
AU732505B2 (en) 2001-04-26
WO1998057661A1 (en) 1998-12-23
CA2292912A1 (en) 1998-12-23
AU8143998A (en) 1999-01-04
JP2002504154A (ja) 2002-02-05
EP1009433A1 (de) 2000-06-21

Similar Documents

Publication Publication Date Title
GB2334444B (en) Hair treatment composition and method of manufacturing the composition
PL317930A1 (en) Oxalydine compounds, method of obtaining them and therapeutic agents
ZA977564B (en) Method of treatment
IL136110A0 (en) Methods and compositions for the treatment of psoriasis
GB9715295D0 (en) Novel method of treatment
EP0975654A4 (de) Zubereitung und verfahren zur behandlung von cmv-infektionen
GB9712866D0 (en) Novel method of treatment
PL336771A1 (en) Method of treating mental diseases among mammals and composition therefor
GB9707693D0 (en) Novel method of treatment
GB9715298D0 (en) Novel method of treatment
EP1009433A4 (de) Therapeutische zusammensetzung und verfahren zur behandlung
GB9715306D0 (en) Novel method of treatment
ZA973988B (en) Method of treatment
GB9618341D0 (en) Method of treatment
AU2992295A (en) Therapeutic method and compounds of use therein
HUP0300043A3 (en) Method and composition for the treatment of pain
GB9608927D0 (en) Method of treatment and pharmaceutical composition
GB9709769D0 (en) Composition and method of treating skin disorders
AUPO616097A0 (en) Composition and method of treatment
AUPO697197A0 (en) Composition and method of treatment
PL342649A1 (en) Prevention of amyloidogenous diseases and treatment of them
ZA987316B (en) Method of treatment
GB9724289D0 (en) Method of treatment
PL329770A1 (en) 3-alkoxypyridine-2-carboxylic amidoesters, method of obtaining them and their application as therapeutic agents
GB9609927D0 (en) Composition and method of treating skin disorders

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991216

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ALTAREX MEDICAL CORP.

A4 Supplementary search report drawn up and despatched

Effective date: 20050202

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07K 16/42 B

Ipc: 7A 61K 39/395 A

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ALTAREX MEDICAL CORPORATION

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080916